Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMAM Dendrimer and Nano-hydroxyapatite for White Spot Lesions
NCT05771077Phase 1Completed
- Sponsor
- Egymedicalpedia
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Hydrogel Systems, Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poly(amidoamine) dendrimer and nanohydroxyapatite in White spot lesion (WSL), sponsored by Egymedicalpedia. Primary endpoint: Remineralization at 3 months. Started Jun 2022; status: completed.
02
Drugs
poly(amidoamine) dendrimernanohydroxyapatite
03
Conditions
White spot lesion (WSL)
Beyond the preview
Go deeper on NCT05771077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771077.